Abstract
Reactive oxygen species (ROS) are produced in all mammalian cells as a result of normal cellular metabolism and due to the activation of oxidant-producing enzymes in response to exogenous stimuli. The balance between ROS production and antioxidant defenses determines the degree of oxidative stress. Generation of ROS has been associated with cell signaling, stress responses, cell proliferation, aging and cancer development. The ability of ROS to induce cellular damage and to cause cell death opens the possibility to exploit this property in the treatment of cancer through a free radical-mediated mechanism.
Keywords: ros, b cells, lymphoproliferative disorders, rituximab, 2-methoxyoestradiol, imexon, arsenic trioxide 1, 4- benzodiazepine
Current Pharmaceutical Design
Title: Cytotoxic Effects on B Lymphocytes Mediated by Reactive Oxygen Species
Volume: 10 Issue: 8
Author(s): Neus Villamor, Emili Montserrat and Dolors Colomer
Affiliation:
Keywords: ros, b cells, lymphoproliferative disorders, rituximab, 2-methoxyoestradiol, imexon, arsenic trioxide 1, 4- benzodiazepine
Abstract: Reactive oxygen species (ROS) are produced in all mammalian cells as a result of normal cellular metabolism and due to the activation of oxidant-producing enzymes in response to exogenous stimuli. The balance between ROS production and antioxidant defenses determines the degree of oxidative stress. Generation of ROS has been associated with cell signaling, stress responses, cell proliferation, aging and cancer development. The ability of ROS to induce cellular damage and to cause cell death opens the possibility to exploit this property in the treatment of cancer through a free radical-mediated mechanism.
Export Options
About this article
Cite this article as:
Villamor Neus, Montserrat Emili and Colomer Dolors, Cytotoxic Effects on B Lymphocytes Mediated by Reactive Oxygen Species, Current Pharmaceutical Design 2004; 10 (8) . https://dx.doi.org/10.2174/1381612043452848
DOI https://dx.doi.org/10.2174/1381612043452848 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design
Current Topics in Medicinal Chemistry Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies
Mini-Reviews in Medicinal Chemistry The ATP-driven Hsp60 Machinery: Biological and Clinical Implications
Current Immunology Reviews (Discontinued) Erythropoietic Porphyrias: Animal Models and Update in Gene-Based Therapies
Current Gene Therapy Targeting of Hsp32 in Solid Tumors and Leukemias: A Novel Approach to Optimize Anticancer Therapy (Supplementry Material)
Current Cancer Drug Targets Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
CNS & Neurological Disorders - Drug Targets Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives
Current Medicinal Chemistry Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications
Current Cancer Drug Targets A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Current Organic Synthesis Triterpene Derivatives as Inhibitors of Protein Involved in the Inflammatory Process: Molecules Interfering with Phospholipase A2, Cycloxygenase, and Lipoxygenase
Current Drug Targets Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Clinical Implications of Methotrexate Pharmacogenetics in Childhood Acute Lymphoblastic Leukaemia
Current Drug Metabolism Intracellular Disposition of Methotrexate in Acute Lymphoblastic Leukemia in Children
Current Drug Metabolism Regulation and Importance of the PI3K/Akt/mTOR Signaling Pathway in Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design Equilibrative Nucleoside Transporters in Fetal Endothelial Dysfunction in Diabetes Mellitus and Hyperglycaemia
Current Vascular Pharmacology